Use of the Biocartis Idyllaâ„¢ Platform for the Detection of Epidermal Growth Factor Receptor, BRAF and KRAS Proto-Oncogene Mutations in Liquid-Based Cytology Specimens from Patients with Non-Small Cell Lung Carcinoma and Pancreatic Adenocarcinoma The study aimed to demonstrate rapid and effective molecular testing on liquid-based cytology (LBC) samples for EGFR, KRAS and BRAF mutations using the Biocartis Idyllaâ„¢. Rapid on-site evaluation (ROSE) LBC samples for patients with non-small cell lung carcinoma (NSCLC) or pancreatic ductal adenocarcinoma (PDAC) were tested for EGFR, KRAS and BRAF mutations based on the relevance to tumour subtype.
The ºÚ°µ±¬ÁÏÍø kindly ask that you spend 15-20 minutes in order to complete a membership survey
This survey is open to both members and non-members, and the outcomes will influence ºÚ°µ±¬ÁÏÍø strategic policy direction over the next 12-24 months.
The information will be useful in planning future ASM meetings, training events & webinars, in particular the topics you would like to see addressed. Your responses will influence the launch of a new ºÚ°µ±¬ÁÏÍø website and the format of the Cytopathology journal.
By engaging with members and non-members alike, we can determine the issues that those in cytology would like to see addressed by the ºÚ°µ±¬ÁÏÍø.
The survey will close on 5pm on 28th May 2022